bullish
Hugel: A Solid Turnaround Story With Resumption of Botulax Sales in China
330 Views27 Jun 2023 22:04
SUMMARY
- Hugel is a solid turnaround story. The recent resumption of its Botulax product sales in China is likely to boost the company's sales and profits in 2023 and 2024.
- Despite this important catalyst, Hugel continues to face potential legal battle with Medytox over the botulinum toxin-related patent in the United States.
- The overall valuation on Hugel remains attractive and it is trading at EV/EBITDA of 7.1x and P/E of 18.2x in 2023.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
- Hugel Inc (145020 KS): Achieves Record High Revenue and Operating Profit in 4Q2320 Feb 2024
- Hugel Inc (145020 KS): Achieves Record High Revenue in 2Q23; Resubmits Marketing Application in US04 Oct 2023
- Hugel: A Solid Turnaround Story With Resumption of Botulax Sales in China27 Jun 2023
- Hugel Inc (145020 KS): Expanding Global Presence Provides Solace Amid Patent Tussle with Competitor27 Jun 2023
- The Fight to Acquire Hugel - GS Group Led Consortium or Goldman Sachs Led Consortium?15 Aug 2021
- Hugel Placement: A 5.2% Block Deal Sale29 Jun 2020
x